Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes.
apoptosis
essential oil
frankincense
melanoma
tumor remission
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
28 May 2019
28 May 2019
Historique:
received:
13
09
2018
accepted:
03
04
2019
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Melanoma is a deadly form of malignancy and according to the World Health Organization 132,000 new cases of melanoma are diagnosed worldwide each year. Surgical resection and chemo/drug treatments opted for early and late stage of melanoma respectively, however detrimental post surgical and chemotherapy consequences are inevitable. Noticeably melanoma drug treatments are associated with liver injuries such as hepatitis and cholestasis which are very common. Alleviation of these clinical manifestations with better treatment options would enhance prognosis status and patients survival. Natural products which induce cytotoxicity with minimum side effects are of interest to achieve high therapeutic efficiency. In this study we investigated anti-melanoma and hepatoprotective activities of frankincense essential oil (FEO) in both
Identifiants
pubmed: 31191820
doi: 10.18632/oncotarget.26930
pii: 26930
pmc: PMC6544398
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3472-3490Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors declare that there is no conflicts of interest.
Références
J Neurooncol. 2000;46(2):97-103
pubmed: 10894362
J Exp Med. 2000 Aug 21;192(4):571-80
pubmed: 10952727
Microbiol Mol Biol Rev. 2000 Dec;64(4):821-46
pubmed: 11104820
Biofactors. 2000;13(1-4):225-30
pubmed: 11237186
Carcinogenesis. 2001 Apr;22(4):559-65
pubmed: 11285189
Oncologist. 2001;6(2):162-76
pubmed: 11306728
Fitoterapia. 2000 Feb;71(1):25-33
pubmed: 11449466
Nature. 2001 Jul 5;412(6842):95-9
pubmed: 11452314
Cancer Res. 2002 Jul 15;62(14):4109-14
pubmed: 12124349
Pediatr Int. 2002 Aug;44(4):400-3
pubmed: 12139565
Genes Dev. 2003 Jun 15;17(12):1475-86
pubmed: 12783855
Expert Opin Drug Saf. 2003 May;2(3):287-304
pubmed: 12904107
J Biol Chem. 1962 Apr;237:1375-6
pubmed: 14482007
Toxicol Lett. 2004 Jul 15;151(2):335-43
pubmed: 15183458
CMAJ. 2005 Feb 1;172(3):367-79
pubmed: 15684121
Int J Mol Med. 2005 Apr;15(4):655-60
pubmed: 15754028
Drug Resist Updat. 2005 Jun;8(3):163-70
pubmed: 15946892
J Ethnopharmacol. 2005 Oct 3;101(1-3):104-9
pubmed: 15970410
J Pharmacol Exp Ther. 1992 Jun;261(3):1143-6
pubmed: 1602379
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89
pubmed: 16305721
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1163-6
pubmed: 16632162
Mol Cancer Ther. 2007 Feb;6(2):752-61
pubmed: 17308071
Mod Pathol. 2007 Apr;20(4):416-26
pubmed: 17384650
J Biol Chem. 2008 Feb 29;283(9):5217-25
pubmed: 18086668
Bioresour Technol. 2008 Dec;99(18):9004-8
pubmed: 18538563
J Exp Clin Cancer Res. 2009 Mar 05;28:31
pubmed: 19265510
Bioresour Technol. 2010 Jun;101(11):4205-11
pubmed: 20133123
Vaccine. 2010 Apr 1;28(16):2846-52
pubmed: 20153795
Mol Cell. 2010 Feb 12;37(3):299-310
pubmed: 20159550
Planta Med. 2010 Aug;76(11):1103-17
pubmed: 20432202
PLoS One. 2010 May 13;5(5):e10626
pubmed: 20498710
Biochim Biophys Acta. 2011 Apr;1813(4):508-20
pubmed: 21146563
Cancer. 2011 Aug 15;117(16):3788-95
pubmed: 21287538
Nutr Cancer. 2011;63(2):161-73
pubmed: 21294053
Gene Ther. 2011 Aug;18(8):827-34
pubmed: 21390072
Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19
pubmed: 21701501
Biochem Biophys Res Commun. 2011 Jul 29;411(2):449-54
pubmed: 21756878
PLoS One. 2011;6(7):e23000
pubmed: 21829575
BMC Complement Altern Med. 2011 Dec 15;11:129
pubmed: 22171782
Semin Respir Crit Care Med. 2012 Feb;33(1):36-45
pubmed: 22447259
Curr Drug Targets. 2012 Jul;13(8):1006-28
pubmed: 22594470
Cell Prolif. 2012 Dec;45(6):487-98
pubmed: 23030059
Anticancer Drugs. 2013 Jan;24(1):1-13
pubmed: 23044722
Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):573-81
pubmed: 23058007
Pigment Cell Melanoma Res. 2013 Jan;26(1):39-57
pubmed: 23095214
BMC Complement Altern Med. 2012 Dec 13;12:253
pubmed: 23237355
Eur J Cancer. 2013 Apr;49(6):1297-304
pubmed: 23290787
Clin Dermatol. 2013 Mar-Apr;31(2):191-9
pubmed: 23438382
Nat Prod Rep. 2013 Oct 11;30(11):1412-37
pubmed: 24056714
BMC Complement Altern Med. 2013 Dec 11;13:350
pubmed: 24325618
Onco Targets Ther. 2014 Feb 19;7:203-9
pubmed: 24570590
Oncol Rep. 2014 Jun;31(6):2713-9
pubmed: 24789439
PLoS One. 2015 Apr 10;10(4):e0124812
pubmed: 25860257
Avicenna J Phytomed. 2015 Mar-Apr;5(2):84-97
pubmed: 25949949
Int J Mol Sci. 2015 Jul 10;16(7):15727-42
pubmed: 26184171
BMC Cancer. 2015 Oct 27;15:807
pubmed: 26503030
Cell Physiol Biochem. 2015;37(4):1572-80
pubmed: 26513239
Oncotarget. 2017 Jul 18;8(29):46801-46817
pubmed: 27086916
Cancer Lett. 2016 Jul 10;377(1):74-86
pubmed: 27091399
Molecules. 2016 Jul 08;21(7):
pubmed: 27399665
Jpn J Clin Oncol. 2017 Feb 11;47(2):175-178
pubmed: 28173241
Cell Death Dis. 2017 Oct 26;8(10):e3133
pubmed: 29072681
Cancer Lett. 2018 Jan 28;413:110-121
pubmed: 29107114
Int J Mol Sci. 2017 Dec 14;18(12):null
pubmed: 29240662
Chem Biodivers. 2018 Feb;15(2):null
pubmed: 29292594
Biochim Open. 2017 Feb 03;4:31-35
pubmed: 29450138
Mol Med Rep. 2018 Jul;18(1):938-944
pubmed: 29845223
J Biol Chem. 1974 Nov 25;249(22):7130-9
pubmed: 4436300
Ann Clin Lab Sci. 1978 Mar-Apr;8(2):127-9
pubmed: 637517
Hepatology. 1983 May-Jun;3(3):428-32
pubmed: 6573294
Gastroenterology. 1980 Feb;78(2):382-92
pubmed: 6985598
J Immunol. 1994 Jul 15;153(2):507-16
pubmed: 8021492